Orelabrutinib,Rituximab and Methotrexate in Newly-diagnosed Primary Central Nervous System Lymphoma(PCNSL)
Status:
Recruiting
Trial end date:
2026-05-30
Target enrollment:
Participant gender:
Summary
This is a prospective single arm,multi-center,phase 2 study,and this study is to evaluate the
efficacy and safety of Orelabrutinib,Rituximab combined with high-dose Methotrexate(RMO) as
first line regimens in the treatments of newly diagnosed primary central nervous system
lymphoma(PCNSL).Objective response and complete response are the primary endpoint.
Phase:
Phase 2
Details
Lead Sponsor:
Affiliated Hospital to Academy of Military Medical Sciences